💊 When a 'Strategy Change' 8-K Means a Company Is Becoming Someone Else

📋 What Showed Up in Our Pipeline This Week

This week, our pipeline processed 50 High-impact material events filed on March 23 — a typical Monday batch in SEC filing season. The event types ranged from major acquisitions (Abbott closing its $21 billion deal for Exact Sciences) to reverse stock splits to leadership changes. Our system classifies each filing by event type, and one came through labeled "Strategy Change."

Strategy Change filings are one of those categories where the label does almost no work. Most Strategy Change 8-Ks describe a company refocusing a product line, divesting a subsidiary, or entering a new market. They're usually worth a read but rarely remarkable.

This one was different.

📄 The 8-K That Changed Everything

On March 23, 2026, NovaBay Pharmaceuticals, Inc. filed an 8-K. Here's what our Material Event Intelligence surfaced from it:

The filing disclosed a complete and immediate exit from the pharmaceutical business. Effective April 3, 2026, NovaBay Pharmaceuticals would cease to exist under that name. In its place: Stablecoin Development Corporation, trading on NYSE American under the ticker SDEV.

CEO Michael Kazley described stablecoins as offering "the best opportunity in digital finance" and stated his goal was to make SDEV "the top public company to tap into the growing stablecoin economy's money flow."

The filing doesn't describe a partial pivot or a new product line alongside existing operations. It describes a complete exit from pharmaceuticals — immediately.

🏥 The Company NovaBay Was

To appreciate how complete this transformation is, it helps to know what NovaBay actually was.

NovaBay was a small pharmaceutical company based in Emeryville, California. Its primary product was Avenova® — an antimicrobial lid and lash solution for eye hygiene, sold primarily through Amazon and retail pharmacies. The company also made wound care products under the NeutroPhase and CelleRx® brands. Revenue for 2024 was approximately $9.8 million, down 6% from the year before, against a net loss of roughly $8.6 million.

Here's the detail that makes this filing even more striking: NovaBay had already sold the Avenova brand — its primary asset — to PRN Physician Recommended Nutriceuticals in January 2025. More than a year before this 8-K was filed.

By the time our pipeline picked up this "Strategy Change" filing, NovaBay's pharmaceutical business was largely already gone. The filing wasn't announcing a pivot so much as confirming what the company had been quietly becoming since early 2026.

🪙 What the Pivot Is Actually Into

Let's talk about the SKY tokens — because this isn't a generic crypto bet.

SKY is the governance token of the Sky Protocol, which most readers may know better by its former name: MakerDAO. MakerDAO was one of the foundational protocols in decentralized finance and the creator of DAI, the first major decentralized stablecoin. In late 2024, MakerDAO rebranded as Sky Protocol, replacing DAI with a new stablecoin called USDS and introducing SKY to replace MKR as the governance token.

The company acquired its tokens in two ways. About 943.6 million SKY tokens were received as part of the $134 million private placement deal (valued at $58 million). The remaining $70.7 million was used to buy another 1.09 billion SKY tokens on the open market at approximately $0.065 per token. By March 16, 2026, staking those tokens had already generated 26.6 million SKY in rewards — a new, ongoing revenue stream that didn't exist when the company was selling eye drops.

The investor list is also worth noting. Tether Investments — the entity linked to USDT, the world's largest stablecoin with a market cap around $145 billion as of March 2026 — participated in this private placement. When the issuer of USDT takes a position in a company building on a competing stablecoin ecosystem, that's an unusual signal about where the major stablecoin players see the market heading.

📖 How to Read a Strategy Change Filing

The NovaBay case illustrates something worth keeping in mind when you browse material events.

"Strategy Change" is one of the broadest event categories our system uses. It applies to everything from "we're expanding into a new geography" to what you've just read: a complete corporate identity replacement. The label is technically accurate in both cases — it's just not descriptive of the magnitude.

NovaBay's filing hits all three markers of the third scenario simultaneously. The pharmaceutical operations are framed as "left behind." The investors are crypto-native (Tether, Framework Ventures). And "Stablecoin Development Corporation" becomes the official legal name on April 3.

The stock reacted accordingly — shares surged roughly 20–26% when the announcement went public on March 23. If you were browsing NovaBay's company page on Stockadora that week and noticed the Strategy Change flag, this is exactly what a closer read would have surfaced.

This is the kind of thing SEC filings tell you that headlines often don't. Not because journalists missed it — but because "pharma company becomes crypto stablecoin developer" is hard to write about without reading the filing first.